6-MERCAPTOPURINE PLASMA-LEVELS IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA - RELATION TO RELAPSE RISK AND MYELOTOXICITY

被引：44
|
作者：
HAYDER, S
LAFOLIE, P
BJORK, O
PETERSON, C
机构：
[1] KAROLINSKA HOSP,DEPT CLIN PHARMACOL,POB 60500,S-10401 STOCKHOLM 60,SWEDEN
[2] KAROLINSKA HOSP,DEPT PEDIAT,S-10401 STOCKHOLM 60,SWEDEN
来源：
THERAPEUTIC DRUG MONITORING | 1989年 / 11卷 / 06期
关键词：
D O I：
10.1097/00007691-198911000-00001
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：617 / 622
页数：6
相关论文
共 50 条
  • [21] THE COURSE OF BIOLOGICAL PARAMETERS AND 6-MERCAPTOPURINE PHARMACOKINETICS DURING MAINTENANCE TREATMENT OF CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA
    HAYDER, S
    BJORK, O
    LAFOLIE, P
    ACTA PAEDIATRICA SCANDINAVICA, 1990, 79 (8-9): : 832 - 837
  • [22] DISTURBANCE OF 6-MERCAPTOPURINE METABOLISM BY COTRIMOXAZOLE IN CHILDHOOD LYMPHOBLASTIC-LEUKEMIA
    REES, CA
    LENNARD, L
    LILLEYMAN, JS
    MADDOCKS, JL
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1984, 12 (02) : 87 - 89
  • [23] CHILDHOOD LYMPHOBLASTIC-LEUKEMIA - SEX DIFFERENCE IN 6-MERCAPTOPURINE UTILIZATION
    LILLEYMAN, JS
    LENNARD, L
    REES, CA
    MORGAN, G
    MADDOCKS, JL
    BRITISH JOURNAL OF CANCER, 1984, 49 (06) : 703 - 707
  • [24] DIURNAL-VARIATION IN 6-MERCAPTOPURINE PHARMACOKINETICS AND MYELOTOXICITY IN CHILDREN WITH LEUKEMIA
    KOREN, G
    LANGEVIN, AM
    OLIVIERI, N
    GIESBRECHT, E
    ZIPURSKY, A
    GREENBERG, M
    PEDIATRIC RESEARCH, 1989, 25 (04) : A69 - A69
  • [25] DETERMINATION OF 6-MERCAPTOPURINE IN ACUTE LYMPHOBLASTIC-LEUKEMIA PATIENTS PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    KATO, Y
    MATSUSHITA, T
    YOKOYAMA, T
    MOHRI, K
    THERAPEUTIC DRUG MONITORING, 1991, 13 (03) : 220 - 225
  • [26] 6-MERCAPTOPURINE IN CEREBROSPINAL-FLUID DURING ORAL-MAINTENANCE THERAPY OF CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA
    HAYDER, S
    LAFOLIE, P
    BJORK, O
    AHSTROM, L
    PETERSON, C
    MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1988, 5 (03): : 187 - 189
  • [27] INTRAINDIVIDUAL VARIATION IN 6-MERCAPTOPURINE PHARMACOKINETICS DURING ORAL-MAINTENANCE THERAPY OF CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA
    LAFOLIE, P
    HAYDER, S
    BJORK, O
    PETERSON, C
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (06) : 599 - 601
  • [28] 6-MERCAPTOPURINE CUMULATIVE DOSE - A CRITICAL FACTOR OF MAINTENANCE THERAPY IN AVERAGE RISK CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    DIBENEDETTO, SP
    GUARDABASSO, V
    RAGUSA, R
    DICATALDO, A
    MIRAGLIA, V
    DAMICO, S
    IPPOLITO, AM
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1994, 11 (03) : 251 - 258
  • [29] Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia
    Tolbert, Jaszianne A.
    Bai, Shasha
    Abdel-Rahman, Susan M.
    August, Keith J.
    Weir, Scott J.
    Kearns, Gregory L.
    Neville, Kathleen A.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (08)
  • [30] CONGENITAL THIOPURINE METHYLTRANSFERASE DEFICIENCY AND 6-MERCAPTOPURINE TOXICITY DURING TREATMENT FOR ACUTE LYMPHOBLASTIC-LEUKEMIA
    LENNARD, L
    GIBSON, BES
    NICOLE, T
    LILLEYMAN, JS
    ARCHIVES OF DISEASE IN CHILDHOOD, 1993, 69 (05) : 577 - 579
12345